Unknown

Dataset Information

0

Synergistic effects of GDNF and VEGF on lifespan and disease progression in a familial ALS rat model.


ABSTRACT: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the progressive loss of motor neurons in the brain and spinal cord. We have recently shown that human mesenchymal stem cells (hMSCs) modified to release glial cell line-derived neurotrophic factor (GDNF) decrease disease progression in a rat model of ALS when delivered to skeletal muscle. In the current study, we determined whether or not this effect could be enhanced by delivering GDNF in concert with other trophic factors. hMSC engineered to secrete GDNF (hMSC-GDNF), vascular endothelial growth factor (hMSC-VEGF), insulin-like growth factor-I (hMSC-IGF-I), or brain-derived neurotrophic factor (hMSC-BDNF), were prepared and transplanted bilaterally into three muscle groups. hMSC-GDNF and hMSC-VEGF prolonged survival and slowed the loss of motor function, but hMSC-IGF-I and hMSC-BDNF did not have any effect. We then tested the efficacy of a combined ex vivo delivery of GDNF and VEGF in extending survival and protecting neuromuscular junctions (NMJs) and motor neurons. Interestingly, the combined delivery of these neurotrophic factors showed a strong synergistic effect. These studies further support ex vivo gene therapy approaches for ALS that target skeletal muscle.

SUBMITTER: Krakora D 

PROVIDER: S-EPMC3734670 | biostudies-literature | 2013 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Synergistic effects of GDNF and VEGF on lifespan and disease progression in a familial ALS rat model.

Krakora Dan D   Mulcrone Patrick P   Meyer Michael M   Lewis Christina C   Bernau Ksenija K   Gowing Genevieve G   Zimprich Chad C   Aebischer Patrick P   Svendsen Clive N CN   Suzuki Masatoshi M  

Molecular therapy : the journal of the American Society of Gene Therapy 20130528 8


Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the progressive loss of motor neurons in the brain and spinal cord. We have recently shown that human mesenchymal stem cells (hMSCs) modified to release glial cell line-derived neurotrophic factor (GDNF) decrease disease progression in a rat model of ALS when delivered to skeletal muscle. In the current study, we determined whether or not this effect could be enhanced by delivering GDNF in concert with othe  ...[more]

Similar Datasets

| S-EPMC2678899 | biostudies-literature
| S-EPMC1925150 | biostudies-literature
| S-EPMC6246740 | biostudies-other
| S-EPMC5404206 | biostudies-literature
| S-EPMC6403180 | biostudies-literature
| S-EPMC6232792 | biostudies-literature
2008-03-27 | GSE10953 | GEO
| S-SCDT-EMM-2018-08888 | biostudies-other
| S-EPMC7017055 | biostudies-literature
| S-EPMC6534356 | biostudies-literature